Sirion Biotech GmbH

  • Land: Deutschland

Nachricht vom 27.04.2015 | 16:49

Viral Vector Technologies from Europe directly accessible in Boston

(DGAP-Media / 2015-04-27 / 16:49)

27 April 2015

Viral Vector Technologies from Europe directly accessible in Boston

Munich based SIRION Biotech about to open office and lab in Boston Massachusetts

München, 27 April 2015, another Germany company from within its highly innovative life science industry expands into the North American markets, SIRION Biotech in Munich. The company is a leader in the field of viral vectors.

Viral vectors (or virus vectors) are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery of new drug, food and cosmetic compounds. Of particular interest are viral vectors in vaccine development such as tumor treatment vaccines.

The company has gained market positions in German speaking countries, Japan, Korea and Israel. It grows fast at a rate of 40% p.a.. Interestingly, the US remains a challenge despite a common belief that similar cultural heritage and technical curiosity should allow for easy market access. Generating new customers is difficult, despite outstanding quality services. Setting up and managing complex project processes and keeping everyone updated, all these developments occur too far away for the Europe based contact. Despite internet and webinars, a sense of distance remains .

SIRION Biotech has over the last 2 years been recruiting and training binational professionals that are now on their way to Boston to establish a physical presence in the US. Boston has a large local market potential and time difference to Europe is only six hours: project inquiries come in in the afternoon, are being discussed with the Europe HQ first thing in the morning, project proposals and quotes are out with potential clients no later than 24 hours. Service levels realized in Europe can thus be offered to US clients as well.


About SIRION Biotech

SIRION Biotech started in Munich in 2007 with the idea of enabling novel cell models closer to reality than ever before. This required the assembly of an all-encompassing, novel viral vector platform. Both, designing de novo viral vectors and the subsequent creation of custom cell models will pave the way for superior compound development in the life sciences. SIRION's technologies have been validated in over 500 single projects with more than 150 academic and industrial partners. As a result, cell models for drug discovery and development have become highly reliable, as have the use of new viral vectors in gene therapy and vaccine studies both for research and clinical studies.

Contact SIRION Biotech USA:
Dr. Carl Christel
PO Box 3
Durham, NH 03824
Tel.: +1-(857) 284 1844


End of Media Release

Issuer: Sirion Biotech GmbH
Key word(s): Services

2015-04-27 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

349225  2015-04-27 

Interview im Fokus

PANTAFLIX: „Starkes Momentum“

Die PANTAFLIX AG ist kraftvoll in allen Geschäftsbereichen unterwegs und will neue Geschäftsfelder erschließen. „Unsere VoD-Plattform wächst rasant. Für PANTAFLIX eröffnen sich derzeit global gesehen Möglichkeiten, die es bis vor Kurzem noch gar nicht gab.“ Vorstandsvorsitzender (CEO) Stefan Langefeld und Chief Production Officer (CPO) Nicolas Paalzow erklären im die nächsten Schritte des Medienkonzerns.

GBC im Fokus

Homes & Holiday AG – Spezialist für Ferienimmobilien jetzt an der Börse

Seit 6.7. ist die Aktie der Home & Holiday AG nun an der Börse München im Qualitätssegment m:access gelistet. Der Handel auf Xetra und Frankfurt ist ebenfalls erfolgt. Damit ist der erste deutsche Ferien-Immobilien-Spezialist auf dem Parkett. Inklusive Pre-IPO-Kapitalerhöhung sind Homes & Holiday rund 5,8 Mio. Euro zur Wachstumsbeschleunigung zugeflossen. Der TOP-3 Makler aus Mallorca will nun noch stärker expandieren. Unser Research ist von den Zukunftsperspektiven überzeugt und empfiehlt die Aktie mit einem Kursziel von 4,83 Euro zum Kauf.

Aktuelle Research-Studie

curasan AG

Original-Research: curasan AG (von Montega AG): Halten

20. Juli 2018